Retatrutide (also known as Reta, LY3437943) is an investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. This page covers what the published research does — and does not — establish about it in relation to fat loss and weight management.
Retatrutide is researched for Weight management, Metabolic health — which is why it appears in discussions of fat loss and weight management.
Research status: Phase III clinical trials — investigational, not yet approved.
How Retatrutide is thought to work
Retatrutide is an investigational "triple agonist" that simultaneously activates the GIP, GLP-1, and glucagon receptors. Adding glucagon-receptor activity is thought to increase energy expenditure on top of the appetite and glycemic effects of GIP/GLP-1, and early trials have shown substantial weight reduction.
What it does not establish
Not FDA-approved. Prescription-grade investigational compound; use only under medical supervision.
Nothing on this page is a recommendation to use Retatrutide, and Selpho publishes no dosing, reconstitution or sourcing information. Read how we decide what goes in the library.
Other peptides researched for Fat Loss
A GLP-1 receptor agonist approved for type 2 diabetes and weight management.
A dual GIP/GLP-1 receptor agonist approved for diabetes and weight management.
A long-acting amylin analog studied for appetite and weight, often with semaglutide.
An investigational GLP-1/glucagon dual agonist studied for weight and liver health.
Frequently asked questions
Phase III clinical trials — investigational, not yet approved. Research relevant to this area covers weight management, metabolic health. That is a description of where the research points, not evidence that it will work for you — and Selpho does not provide dosing or medical advice.
Phase III clinical trials — investigational, not yet approved.
Not FDA-approved. Prescription-grade investigational compound; use only under medical supervision. Always speak to a licensed healthcare professional before considering any peptide.
An investigational triple GIP/GLP-1/glucagon receptor agonist studied for obesity and metabolic disease. It has drawn attention for strong weight-loss results in trials.
No. It is investigational and in clinical trials — not FDA-approved and not commercially available as a medicine.
Is Retatrutide right for your situation?
Describe your goals and the free Peptide Advisor will match them against the research — no signup, no sales pitch.
Ask the Advisor — freeThis page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.